Impedimed (ASX:IPD) — Material Events
ASX:IPD · 11 articles in the last 12 months · 100% assessed
Click a band to jump to that tier
Major ≥90
Significant 75–89
Notable 50–74
Routine <50
Not assessed
ImpediMed Raises A$15.2 Million to Fuel Growth and Cut Costs, Eyes FY28 Cashflow BreakevenHigh
ImpediMed launches AUD 15.2m equity raise to fund growth and debt reduction, targeting cashflow breakeven by H2 FY28
4 May 2026
·Equity Raising
·85
ImpediMed Hits Record $6.3M SOZO Sales Amid US Reimbursement BoostMedium
ImpediMed posts record SOZO sales, expands US reimbursement, and secures $5M funding tranche
31 July 2025
·Quarterly Activity and Cash Flow Report
·85
ImpediMed Doubles US Sales, Unlocks $5M Growth Capital TrancheMedium
ImpediMed doubles Q4 US sales, secures additional US$5M funding tranche
16 July 2025
·Quarterly Sales and Capital Facility Update
·85
Major US Insurer Boosts Coverage for ImpediMed’s Lymphedema Assessment TechMedium
Major US Insurer Expands Coverage for ImpediMed's Lymphedema Assessment Technology
2 Oct 2025
·ASX Announcement
·85
ImpediMed Posts Record Revenue Amid US Expansion and SOZO Pro LaunchMedium
ImpediMed posts record quarterly revenue, expands US hospital footprint, and launches SOZO Pro
30 Oct 2025
·Quarterly Activity and Cash Flow Report
·80
ImpediMed Advances with $3.9M Revenue and Expanding US Heart Health PushMedium
ImpediMed Q2 FY26: $3.9M Revenue, Strong BCRL Reimbursement Gains, US Heart Health Launch
29 Jan 2026
·Quarterly Activity and Cash Flow Report
·75
ImpediMed Appoints Erik Anderson as CEO to Accelerate US Commercial GrowthMedium
ImpediMed appoints Erik Anderson as CEO to drive US growth and commercial execution
7 Apr 2026
·Executive Appointment
·75
ImpediMed Raises $2.1 Million in Oversubscribed Share Purchase Plan After $13.2 Million PlacementMedium
ImpediMed completes oversubscribed $2.1 million Share Purchase Plan following $13.2 million placement
10 June 2026
·Capital Raising
·75
ImpediMed Strengthens Leadership and Sales Momentum Amid Strategic GrowthMedium
ImpediMed updates on leadership, sales momentum, and strategic growth initiatives
2 June 2026
·CEO Business Update
·70
ImpediMed Expands US Reimbursement to 94% as New CEO Takes HelmMedium
ImpediMed Q3 FY26 revenue $3.5M, expands US reimbursement, appoints new CEO to drive growth
30 Apr 2026
·Quarterly Activity and Cash Flow Report
·70
ImpediMed Reports 23% Revenue Growth Amid Rising Losses in FY2025Medium
ImpediMed FY2025 revenue up 23%, net loss widens 17%, no dividends declared
28 Aug 2025
·Appendix 4E - Preliminary Final Report
·60
No articles in this tier for the last 12 months.
Market Mentions
5
- appeared in market wrap coverage
These are market wrap articles where Impedimed (ASX:IPD) was mentioned. They reflect broader market coverage, not company-specific announcements.
Healthcare Wrap - Week 24 (8 June -> 12 June) 2026
13 June 2026
Healthcare Wrap - Week 23 (1 June -> 5 June) 2026
6 June 2026
Market Wrap - Week 19 (4 May -> 8 May) 2026
9 May 2026
Healthcare Wrap - Week 19 (4 May -> 8 May) 2026
9 May 2026
Healthcare Wrap - Week 15 (6 Apr -> 10 Apr) 2026
11 Apr 2026